Abstract PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer

富维斯特朗 医学 药效学 转移性乳腺癌 不利影响 乳腺癌 内科学 雌激素受体 肿瘤科 癌症 药理学 药代动力学
作者
Erika Hamilton,Linda T. Vahdat,Hyo S. Han,J. Ranciato,Richard Gedrich,Chi Fung Keung,Deborah Chirnomas,Sara A. Hurvitz
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (4_Supplement): PD13-08 被引量:28
标识
DOI:10.1158/1538-7445.sabcs21-pd13-08
摘要

Abstract Background: Resistance to current endocrine therapies remains a clinical challenge. Fulvestrant has established estrogen receptor (ER) degradation as a critical therapeutic strategy characterized by approximately 50% ER degradation, a clinical benefit rate (CBR) of < 20% in the post CDK 4/6 setting, and a suboptimal intramuscular route of administration. ARV-471 is a selective, orally bioavailable PROteolysis-TArgeting Chimera (PROTAC®) small molecule that induces degradation of wildtype and mutant ER. ARV-471 demonstrates superior ER degradation and antitumor activity compared to fulvestrant in endocrine sensitive and resistant xenograft models. Methods: This is a multi-center, first-in-human, open label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ARV-471 administered orally in patients with ER+/HER2- advanced/metastatic breast cancer. The phase 1 monotherapy dose escalation used a 3+3 design with backfill to assess ARV-471 in pre-/post-menopausal women. Premenopausal women had to be on ovarian suppression. Patients were required to have received at least one prior CDK 4/6 inhibitor and at least 2 prior endocrine therapies. Up to 3 prior lines of chemotherapy were allowed. Results: As of June 6th, 2021, 50 patients were treated in the monotherapy escalation at total daily doses of 30mg (n=3), 60mg (n=3), 120mg (n=7), 180/200mg (n=11), 360mg (n=15), 500mg (n=8), and maximum administered dose of 700mg (n=3). A maximum tolerated dose was not reached and no dose limiting toxicities (DLTs) were observed. The most common (≥ 10%) treatment related adverse events (TRAEs) were nausea (24%), fatigue (12%), and vomiting (10%) that were predominantly grade 1 in severity. Two patients experienced grade 3 adverse events (AEs) that were potentially related to ARV-471: 1 patient treated at 180mg had a transient headache lasting 1 day, and 1 patient treated at 360mg had a venous thromboembolism (VTE) a few days after a minor procedure. There were no AEs > grade 3 potentially related to ARV-471. All AEs were manageable with only one patient discontinuing ARV-471 due to a TRAE (grade 3 VTE). ARV-471 demonstrated a dose-related increase in plasma exposure up to 500mg, with doses of 60mg daily and above resulting in steady-state Cmax and AUC24 that exceeded the exposure associated with tumor regression in preclinical models. Analysis of 12 paired biopsies from patients treated at 30 to 360mg daily demonstrated up to 90% ER degradation in tumors expressing WT or mutant ER. Of 34 patients who were evaluable for clinical benefit (confirmed complete response, partial response, or stable disease ≥ 24 weeks) the CBR was 41%. As of the data cutoff date, 6 of the 34 patients were continuing to receive study treatment, including 2 patients who had been on treatment for over 16 months. Two confirmed partial responses were observed among the 28 patients with baseline measurable disease and at least 1 on-treatment tumor assessment. Conclusion: ARV-471 was well tolerated with no DLTs at total daily doses up to 700mg. ARV-471 demonstrated robust ER degradation in paired biopsy samples and encouraging clinical activity (41% CBR) in patients who received prior CDK 4/6 inhibitors. ARV-471 is now being evaluated in the VERITAC Phase 2 monotherapy expansion at 200 mg and 500 mg once daily. Citation Format: Erika Hamilton, Linda Vahdat, Hyo S Han, Jennifer Ranciato, Richard Gedrich, Chi F Keung, Deborah Chirnomas, Sara Hurvitz. First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD13-08.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
沐浴清风发布了新的文献求助10
2秒前
星辰大海应助buger采纳,获得10
2秒前
4秒前
许琳琳完成签到 ,获得积分10
4秒前
李健应助小王小王采纳,获得10
5秒前
6秒前
风中泰坦给风中泰坦的求助进行了留言
6秒前
ATOM完成签到,获得积分10
7秒前
7秒前
8秒前
冷酷思远发布了新的文献求助30
9秒前
YongXin发布了新的文献求助30
9秒前
YYYZZX1发布了新的文献求助10
10秒前
10秒前
研友_VZG7GZ应助1122333月采纳,获得10
11秒前
11秒前
11秒前
12秒前
..完成签到,获得积分10
12秒前
WC发布了新的文献求助10
13秒前
曾经语芙完成签到,获得积分20
15秒前
风中泰坦发布了新的文献求助10
15秒前
17秒前
羊羊发布了新的文献求助10
18秒前
Hemingwayway发布了新的文献求助10
18秒前
潘小科发布了新的文献求助10
19秒前
Lijunjie完成签到,获得积分10
19秒前
qmx发布了新的文献求助10
20秒前
是十二呀关注了科研通微信公众号
20秒前
zgghbb完成签到,获得积分20
21秒前
21秒前
繁星完成签到,获得积分10
21秒前
是微微发布了新的文献求助10
22秒前
丰盛的煎饼应助77采纳,获得20
22秒前
落星发布了新的文献求助10
23秒前
23秒前
Hemingwayway完成签到,获得积分10
24秒前
24秒前
诚心谷南完成签到,获得积分20
25秒前
高分求助中
中国国际图书贸易总公司40周年纪念文集 大事记1949-1987 2000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
草地生态学 880
Threaded Harmony: A Sustainable Approach to Fashion 799
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3058079
求助须知:如何正确求助?哪些是违规求助? 2714263
关于积分的说明 7439873
捐赠科研通 2359489
什么是DOI,文献DOI怎么找? 1250095
科研通“疑难数据库(出版商)”最低求助积分说明 607383
版权声明 596392